Biome Australia Limited (BIO.AX)
AUD 0.46
(0.0%)
AUD 0.46
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 7.91 Million AUD | 7.88% |
| 2023 | 7.33 Million AUD | 2.54% |
| 2022 | 7.15 Million AUD | 8.42% |
| 2021 | 6.59 Million AUD | 132.52% |
| 2020 | 2.83 Million AUD | 33.96% |
| 2019 | 2.11 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 5.08 Million AUD | 99.17% |
| 2024 FY | 9.58 Million AUD | 30.68% |
| 2024 Q4 | 4.49 Million AUD | 0.0% |
| 2024 Q1 | 2.55 Million AUD | -33.97% |
| 2023 Q2 | 3.46 Million AUD | 86.18% |
| 2023 FY | 7.33 Million AUD | 2.54% |
| 2023 Q4 | 3.86 Million AUD | 113.26% |
| 2023 Q3 | 1.81 Million AUD | -47.72% |
| 2023 Q1 | 1.86 Million AUD | -39.88% |
| 2022 Q1 | 1.74 Million AUD | -41.49% |
| 2022 FY | 7.15 Million AUD | 8.42% |
| 2022 Q4 | 3.09 Million AUD | 81.77% |
| 2022 Q3 | 1.7 Million AUD | -50.36% |
| 2022 Q2 | 3.43 Million AUD | 96.52% |
| 2021 Q3 | 1.35 Million AUD | -62.33% |
| 2021 Q4 | 2.98 Million AUD | 119.58% |
| 2021 FY | 6.59 Million AUD | 132.52% |
| 2021 Q1 | 1.88 Million AUD | 0.0% |
| 2021 Q2 | 3.6 Million AUD | 91.03% |
| 2020 FY | 2.83 Million AUD | 33.96% |
| 2019 FY | 2.11 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | -16.866% |
| Acrux Limited | 8.55 Million AUD | 7.471% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -1214.549% |
| BTC Health Limited | -1.03 Million AUD | 861.48% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 59.978% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 85.95% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 74.722% |
| Hexima Limited | 1 Million AUD | -684.26% |
| Immutep Limited | 42.87 Million AUD | 81.548% |
| Memphasys Limited | 3.67 Million AUD | -115.073% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 75.804% |
| Noxopharm Limited | 7 Million AUD | -13.014% |
| Prescient Therapeutics Limited | 10.89 Million AUD | 27.412% |
| Race Oncology Limited | 14.77 Million AUD | 46.439% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -2543.877% |
| Starpharma Holdings Limited | 22.81 Million AUD | 65.326% |
| Tissue Repair Ltd | 6.66 Million AUD | -18.666% |
| Biotron Limited | 5.11 Million AUD | -54.798% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 66.201% |
| CSL Limited | 7.56 Billion AUD | 99.895% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 80.009% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -1013.916% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -186.533% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -32.995% |
| Patrys Limited | 4.93 Million AUD | -60.363% |
| Orthocell Limited | 15.36 Million AUD | 48.527% |
| Imugene Limited | 135.09 Million AUD | 94.144% |
| PYC Therapeutics Limited | 60.91 Million AUD | 87.013% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -786.766% |
| Cynata Therapeutics Limited | 11.12 Million AUD | 28.879% |
| Arovella Therapeutics Limited | 10.78 Million AUD | 26.648% |
| Nanollose Limited | 12.5 Thousand AUD | -63184.705% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -136.446% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -302.561% |
| Amplia Therapeutics Limited | 8.43 Million AUD | 6.218% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -91.771% |
| Nyrada Inc. | 4.55 Million AUD | -73.676% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 97.062% |
| Dimerix Limited | 25.64 Million AUD | 69.149% |
| PharmAust Limited | 6.65 Million AUD | -18.841% |
| AnteoTech Limited | 12.18 Million AUD | 35.085% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 87.848% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 63.517% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -74.049% |
| Actinogen Medical Limited | 22.77 Million AUD | 65.257% |
| Immuron Limited | 9.13 Million AUD | 13.424% |
| Argenica Therapeutics Limited | 8.26 Million AUD | 4.328% |